| Levosalbutamol | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
| Levosalbutamol | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
| Levosalbutamol | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
| Levosalbutamol | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa01522 | Endocrine resistance | 2.16E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04012 | ErbB signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04014 | Ras signaling pathway | 3.65E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04015 | Rap1 signaling pathway | 2.99E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04022 | cGMP-PKG signaling pathway | 3.15E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04024 | cAMP signaling pathway | 2.49E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04062 | Chemokine signaling pathway | 3.98E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04071 | Sphingolipid signaling pathway | 3.35E-03 | 5 | P04049, P21453, Q9H228, P01375, Q13362 | RAF1, S1PR1, EDG8, TNF, PPP2R5C | More | |
| Levosalbutamol | hsa04072 | Phospholipase D signaling pathway | 2.82E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | |
| Levosalbutamol | hsa04140 | Autophagy - animal | 2.82E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04150 | mTOR signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04210 | Apoptosis | 2.16E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04213 | Longevity regulating pathway - multiple species | 2.85E-02 | 2 | Q9Y4H2, Q13547 | IRS2, HDAC1 | More | |
| Levosalbutamol | hsa04218 | Cellular senescence | 2.49E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | |
| Levosalbutamol | hsa04270 | Vascular smooth muscle contraction | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04360 | Axon guidance | 2.49E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04370 | VEGF signaling pathway | 8.29E-03 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04371 | Apelin signaling pathway | 2.65E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04510 | Focal adhesion | 3.48E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04540 | Gap junction | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
| Levosalbutamol | hsa04613 | Neutrophil extracellular trap formation | 5.32E-05 | 6 | P04049, P11215, Q13547, P58876, Q16778, O60814 | RAF1, ITGAM, HDAC1, H2BC5, HIST2H2BE, H2BC12 | More | |
| Levosalbutamol | hsa04625 | C-type lectin receptor signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04630 | JAK-STAT signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04650 | Natural killer cell mediated cytotoxicity | 2.93E-05 | 8 | P01375, P20963, P04049, Q13241, P26718, P26717, Q14953, P26715 | TNF, CD247, RAF1, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | |
| Levosalbutamol | hsa04657 | IL-17 signaling pathway | 2.41E-02 | 4 | P19875, P14780, P80188, P01375 | CXCL2, MMP9, LCN2, TNF | More | |
| Levosalbutamol | hsa04660 | T cell receptor signaling pathway | 1.66E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04662 | B cell receptor signaling pathway | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04664 | Fc epsilon RI signaling pathway | 1.16E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04666 | Fc gamma R-mediated phagocytosis | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | |
| Levosalbutamol | hsa04720 | Long-term potentiation | 1.66E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04722 | Neurotrophin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04726 | Serotonergic synapse | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04730 | Long-term depression | 1.16E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | |
| Levosalbutamol | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | |
| Levosalbutamol | hsa04810 | Regulation of actin cytoskeleton | 3.81E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04910 | Insulin signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04912 | GnRH signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | |
| Levosalbutamol | hsa04914 | Progesterone-mediated oocyte maturation | 2.16E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04915 | Estrogen signaling pathway | 2.99E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04916 | Melanogenesis | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04917 | Prolactin signaling pathway | 6.63E-03 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04919 | Thyroid hormone signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04921 | Oxytocin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | |
| Levosalbutamol | hsa04926 | Relaxin signaling pathway | 6.24E-03 | 5 | P18848, P22694, P14780, P04049, P30679 | ATF4, PRKACB, MMP9, RAF1, GNA15 | More | |
| Levosalbutamol | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | |
| Levosalbutamol | hsa04928 | Parathyroid hormone synthesis, secretion and action | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04929 | GnRH secretion | 4.98E-03 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04935 | Growth hormone synthesis, secretion and action | 2.16E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | |
| Levosalbutamol | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | |
| Levosalbutamol | hsa05034 | Alcoholism | 1.49E-04 | 5 | Q13547, P04049, P58876, Q16778, O60814 | HDAC1, RAF1, H2BC5, HIST2H2BE, H2BC12 | More | |
| Levosalbutamol | hsa05132 | Salmonella infection | 4.98E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | |
| Levosalbutamol | hsa05146 | Amoebiasis | 2.41E-02 | 4 | P19875, P01375, P30679, P22694 | CXCL2, TNF, GNA15, PRKACB | More | |
| Levosalbutamol | hsa05152 | Tuberculosis | 3.98E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa05160 | Hepatitis C | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa05161 | Hepatitis B | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa05163 | Human cytomegalovirus infection | 4.98E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa05164 | Influenza A | 3.65E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 3.15E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa05170 | Human immunodeficiency virus 1 infection | 3.48E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa05202 | Transcriptional misregulation in cancer | 1.24E-02 | 4 | P27930, P11215, Q13547, P12980 | IL1R2, ITGAM, HDAC1, LYL1 | More | |
| Levosalbutamol | hsa05203 | Viral carcinogenesis | 6.44E-03 | 4 | Q13547, P58876, Q16778, O60814 | HDAC1, H2BC5, HIST2H2BE, H2BC12 | More | |
| Levosalbutamol | hsa05205 | Proteoglycans in cancer | 1.09E-02 | 6 | P04049, P14780, P01375, P23588, Q13635, P22694 | RAF1, MMP9, TNF, EIF4B, PTCH1, PRKACB | More | |
| Levosalbutamol | hsa05206 | MicroRNAs in cancer | 3.15E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa05210 | Colorectal cancer | 1.66E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa05211 | Renal cell carcinoma | 1.16E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa05212 | Pancreatic cancer | 1.16E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa05213 | Endometrial cancer | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa05214 | Glioma | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa05218 | Melanoma | 6.63E-03 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa05219 | Bladder cancer | 4.98E-03 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa05220 | Chronic myeloid leukemia | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa05221 | Acute myeloid leukemia | 8.29E-03 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa05223 | Non-small cell lung cancer | 6.63E-03 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa05224 | Breast cancer | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa05226 | Gastric cancer | 8.29E-03 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa05230 | Central carbon metabolism in cancer | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa05231 | Choline metabolism in cancer | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.66E-02 | 1 | P04049 | RAF1 | More | |
| Levosalbutamol | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | |
| Levosalbutamol | hsa05322 | Systemic lupus erythematosus | 1.18E-02 | 3 | P58876, Q16778, O60814 | H2BC5, HIST2H2BE, H2BC12 | More | |
| Levosalbutamol | hsa05332 | Graft-versus-host disease | 8.79E-03 | 3 | P01375, P26715, Q13241 | TNF, KLRC1, KLRD1 | More | |
| Salbutamol | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
| Salbutamol | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
| Salbutamol | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
| Salbutamol | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa01522 | Endocrine resistance | 2.16E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04012 | ErbB signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04014 | Ras signaling pathway | 3.65E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04015 | Rap1 signaling pathway | 2.99E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04022 | cGMP-PKG signaling pathway | 3.15E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04024 | cAMP signaling pathway | 2.49E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04062 | Chemokine signaling pathway | 3.98E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04071 | Sphingolipid signaling pathway | 3.35E-03 | 5 | P04049, P21453, Q9H228, P01375, Q13362 | RAF1, S1PR1, EDG8, TNF, PPP2R5C | More | |
| Salbutamol | hsa04072 | Phospholipase D signaling pathway | 2.82E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | |
| Salbutamol | hsa04140 | Autophagy - animal | 2.82E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04150 | mTOR signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04210 | Apoptosis | 2.16E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04213 | Longevity regulating pathway - multiple species | 2.85E-02 | 2 | Q9Y4H2, Q13547 | IRS2, HDAC1 | More | |
| Salbutamol | hsa04218 | Cellular senescence | 2.49E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | |
| Salbutamol | hsa04270 | Vascular smooth muscle contraction | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04360 | Axon guidance | 2.49E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04370 | VEGF signaling pathway | 8.29E-03 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04371 | Apelin signaling pathway | 2.65E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04510 | Focal adhesion | 3.48E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04540 | Gap junction | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
| Salbutamol | hsa04613 | Neutrophil extracellular trap formation | 5.32E-05 | 6 | P04049, P11215, Q13547, P58876, Q16778, O60814 | RAF1, ITGAM, HDAC1, H2BC5, HIST2H2BE, H2BC12 | More | |
| Salbutamol | hsa04625 | C-type lectin receptor signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04630 | JAK-STAT signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04650 | Natural killer cell mediated cytotoxicity | 2.93E-05 | 8 | P01375, P20963, P04049, Q13241, P26718, P26717, Q14953, P26715 | TNF, CD247, RAF1, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | |
| Salbutamol | hsa04657 | IL-17 signaling pathway | 2.41E-02 | 4 | P19875, P14780, P80188, P01375 | CXCL2, MMP9, LCN2, TNF | More | |
| Salbutamol | hsa04660 | T cell receptor signaling pathway | 1.66E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04662 | B cell receptor signaling pathway | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04664 | Fc epsilon RI signaling pathway | 1.16E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04666 | Fc gamma R-mediated phagocytosis | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | |
| Salbutamol | hsa04720 | Long-term potentiation | 1.66E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04722 | Neurotrophin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04726 | Serotonergic synapse | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04730 | Long-term depression | 1.16E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | |
| Salbutamol | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | |
| Salbutamol | hsa04810 | Regulation of actin cytoskeleton | 3.81E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04910 | Insulin signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04912 | GnRH signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | |
| Salbutamol | hsa04914 | Progesterone-mediated oocyte maturation | 2.16E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04915 | Estrogen signaling pathway | 2.99E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04916 | Melanogenesis | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04917 | Prolactin signaling pathway | 6.63E-03 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04919 | Thyroid hormone signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04921 | Oxytocin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | |
| Salbutamol | hsa04926 | Relaxin signaling pathway | 6.24E-03 | 5 | P18848, P22694, P14780, P04049, P30679 | ATF4, PRKACB, MMP9, RAF1, GNA15 | More | |
| Salbutamol | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | |
| Salbutamol | hsa04928 | Parathyroid hormone synthesis, secretion and action | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04929 | GnRH secretion | 4.98E-03 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04935 | Growth hormone synthesis, secretion and action | 2.16E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | |
| Salbutamol | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | |
| Salbutamol | hsa05034 | Alcoholism | 1.49E-04 | 5 | Q13547, P04049, P58876, Q16778, O60814 | HDAC1, RAF1, H2BC5, HIST2H2BE, H2BC12 | More | |
| Salbutamol | hsa05132 | Salmonella infection | 4.98E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | |
| Salbutamol | hsa05146 | Amoebiasis | 2.41E-02 | 4 | P19875, P01375, P30679, P22694 | CXCL2, TNF, GNA15, PRKACB | More | |
| Salbutamol | hsa05152 | Tuberculosis | 3.98E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa05160 | Hepatitis C | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa05161 | Hepatitis B | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa05163 | Human cytomegalovirus infection | 4.98E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa05164 | Influenza A | 3.65E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 3.15E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa05170 | Human immunodeficiency virus 1 infection | 3.48E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa05202 | Transcriptional misregulation in cancer | 1.24E-02 | 4 | P27930, P11215, Q13547, P12980 | IL1R2, ITGAM, HDAC1, LYL1 | More | |
| Salbutamol | hsa05203 | Viral carcinogenesis | 6.44E-03 | 4 | Q13547, P58876, Q16778, O60814 | HDAC1, H2BC5, HIST2H2BE, H2BC12 | More | |
| Salbutamol | hsa05205 | Proteoglycans in cancer | 1.09E-02 | 6 | P04049, P14780, P01375, P23588, Q13635, P22694 | RAF1, MMP9, TNF, EIF4B, PTCH1, PRKACB | More | |
| Salbutamol | hsa05206 | MicroRNAs in cancer | 3.15E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa05210 | Colorectal cancer | 1.66E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa05211 | Renal cell carcinoma | 1.16E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa05212 | Pancreatic cancer | 1.16E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa05213 | Endometrial cancer | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa05214 | Glioma | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa05218 | Melanoma | 6.63E-03 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa05219 | Bladder cancer | 4.98E-03 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa05220 | Chronic myeloid leukemia | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa05221 | Acute myeloid leukemia | 8.29E-03 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa05223 | Non-small cell lung cancer | 6.63E-03 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa05224 | Breast cancer | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa05226 | Gastric cancer | 8.29E-03 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa05230 | Central carbon metabolism in cancer | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa05231 | Choline metabolism in cancer | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.66E-02 | 1 | P04049 | RAF1 | More | |
| Salbutamol | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | |
| Salbutamol | hsa05322 | Systemic lupus erythematosus | 1.18E-02 | 3 | P58876, Q16778, O60814 | H2BC5, HIST2H2BE, H2BC12 | More | |
| Salbutamol | hsa05332 | Graft-versus-host disease | 8.79E-03 | 3 | P01375, P26715, Q13241 | TNF, KLRC1, KLRD1 | More | |
